Skip to content

Study · Ex vivo tissue · frog · 1995

5 results

Frog vasoactive intestinal polypeptide and galanin: primary structures and effects on pituitary adenylate cyclase.

Chartrel N, Wang Y, Fournier A, Vaudry H, Conlon JM

Endocrinology1 Jul 1995Cited by 51 (Europe PMC)

PMID7540547 (opens in a new tab)DOI10.1210/endo.136.7.7540547 (opens in a new tab)PepBankPUB-07540547
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In frog anterior pituitary fragments, the potency of frog VIP for cAMP increase was comparable to that of porcine VIP.

    In plain wordsIn lab tests on frog pituitary tissue, frog VIP worked about as strongly as pig VIP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changePotency of frog VIP versus porcine VIP
    Study

    frogn = 8

    Frog anterior pituitary fragments
    Comparator
    Porcine VIP
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The potency of the peptide (ED50 = 1.2 x 10(-6) M; mean +/- SE; n = 8) was comparable to that of porcine VIP (EC50 = 1.3 x 10(-6) M)
  2. 02LabEx vivo tissueActivity measurement

    In frog anterior pituitary fragments, synthetic frog VIP produced a dose-dependent increase in cAMP concentration.

    In plain wordsIn lab tests on frog pituitary tissue, frog VIP raised cAMP in a dose-dependent way.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasecAMP concentration in frog anterior pituitary fragments
    Study

    frogn: not reported in source

    Frog anterior pituitary fragments
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Synthetic frog VIP produced a dose-dependent increase in cAMP concentration in frog anterior pituitary fragments.
  3. 03LabEx vivo tissueActivity measurement

    In frog anterior pituitary fragments, frog VIP was approximately 10-fold less potent than frog PACAP-(1-38) for cAMP increase.

    In plain wordsIn lab tests on frog pituitary tissue, frog VIP worked about ten times less strongly than frog PACAP.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreasePotency of frog VIP versus frog PACAP-(1-38)
    Study

    frogn: not reported in source

    Frog anterior pituitary fragments
    Comparator
    Frog PACAP-(1-38)
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but was approximately 10-fold less than that of frog pituitary adenylate cyclase-activating polypeptide [PACAP-(1-38); ED50 = 1.1 x 10(-7) M] in the same system.
  4. 04LabEx vivo tissueMechanism

    In frog anterior pituitary fragments, cAMP increases from maximal doses of PACAP and VIP were not additive.

    In plain wordsIn lab tests on frog pituitary tissue, giving PACAP and VIP together at top doses did not raise cAMP more than each alone.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeAdditivity of maximal VIP and PACAP cAMP responses
    Study

    frogn: not reported in source

    Frog anterior pituitary fragments
    Comparator
    PACAP
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The increases in cAMP concentrations produced by maximal doses of PACAP (10(-5) M) and VIP (10(-5) M) were not additive.

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneOther designOther

    Frog VIP isolated from the stomach of Rana ridibunda is identical to the VIP of chicken and alligator.

    In plain wordsIn lab analysis, VIP from the green frog stomach has the same amino acid sequence as VIP from chicken and alligator.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableFrog VIP primary structure
    Study

    frogn: not reported in source

    Peptide isolated from Rana ridibunda stomach
    Outcome group
    Peptide structure and chemistry · Pharmacology

    Source sentences

    Summary
    Frog VIP is identical to the previously characterized VIP from chicken and alligator.
    1 context sentence
    Summary · context
    Vasoactive intestinal polypeptide (VIP) and galanin were isolated in pure form from the stomach of the European green frog, Rana ridibunda.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.